Welcome, Guest. Please login or register.
April 26, 2024, 01:41:47 am

Login with username, password and session length


Members
  • Total Members: 6307
  • Latest: golfer
Stats
  • Total Posts: 55126
  • Total Topics: 4851
  • Online Today: 129
  • Online Ever: 1314
  • (June 22, 2016, 05:23:42 am)
Users Online
Users: 0
Guests: 96
Total: 96

Welcome

Welcome to the Hep Forums, a round-the-clock discussion area for people who have Fatty Liver Disease, Hepatitis B, C or a co-infection, their friends and family and others with questions about hepatitis and liver health. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Hep Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Merck’s Triple-Drug Hep C Combo Cures Almost All of Retreated Group  (Read 5243 times)

0 Members and 1 Guest are viewing this topic.

Offline Hep Editors

  • Member
  • Posts: 784
    • Hep Mag
In a recent trial, Merck’s triple-drug hepatitis C virus (HCV) regimen cured nearly all those with genotype 1 of the virus who had failed a previous cure attempt, aidsmap reports.

The C-SURGE trial included 94 people with genotype 1, mostly those with genotype 1a (as opposed to genotype 1b). They were randomly assigned to receive once-daily grazoprevir/uprifosbuvir/ruzasvir with ribavirin for 16 weeks or without ribavirin for 24 weeks.

Findings were presented at the 52nd International Liver Congress in Amsterdam.

Read more...
https://www.hepmag.com/article/mercks-tripledrug-hep-c-combo-cures-almost-retreated-group

 


© 2024 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.